These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2124944)

  • 1. Phase II trial of ifosfamide in the treatment of metastatic hormone-refractory patients with prostatic cancer.
    Mahjoubi M; Azab M; Ghosn M; Theodore C; Droz JP
    Cancer Invest; 1990; 8(5):477-81. PubMed ID: 2124944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
    Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study.
    Williamson SK; Wolf MK; Eisenberger MA; O'Rourke MA; Brannon W; Crawford ED
    Am J Clin Oncol; 1996 Aug; 19(4):368-70. PubMed ID: 8677906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Homesley HD; McGuire WP; Adcock L
    Cancer; 1994 Mar; 73(5):1453-5. PubMed ID: 8111713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
    Sørensen P; Pfeiffer P; Bertelsen K
    Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Olver I; Keefe D; Myers M; Caruso D
    Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
    Sutton G; Blessing JA; Park R; DiSaia PJ; Rosenshein N
    Obstet Gynecol; 1996 May; 87(5 Pt 1):747-50. PubMed ID: 8677079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study.
    Bisagni G; Boni C; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A; Savoldi L
    Tumori; 1998; 84(6):659-61. PubMed ID: 10080671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
    Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
    J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; McGuire WP; Patton T; Look KY
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):805-7. PubMed ID: 8456884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
    Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
    J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
    Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B study 8552.
    Case DC; Anderson J; Ervin TJ; Gottlieb A
    Hematol Oncol; 1991; 9(4-5):189-96. PubMed ID: 1743622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
    Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
    Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
    Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
    J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.